|Bid||47.48 x 800|
|Ask||47.36 x 800|
|Day's Range||47.28 - 48.27|
|52 Week Range||36.28 - 80.66|
|Beta (3Y Monthly)||1.91|
|PE Ratio (TTM)||56.71|
|Earnings Date||Aug 7, 2019 - Aug 12, 2019|
|Forward Dividend & Yield||0.84 (1.75%)|
|1y Target Est||56.33|
NEW YORK , May 22, 2019 /PRNewswire/ -- Juan Monteverde , founder and managing partner at Monteverde & Associates PC , a national securities firm headquartered at the Empire State Building in New York ...
TASE: PRGO) today announced its partner received final approval from the U.S. Food and Drug Administration for its AB rated Abbreviated New Drug Application (ANDA) referencing Voltaren® Gel, 1% (diclofenac sodium topical gel, 1%). Perrigo will acquire full ownership of the ANDA under a pre-existing arrangement with its partner within 30 days. Perrigo will manufacture diclofenac sodium topical gel 1% in its plant in Israel.
Every investor in Perrigo Company plc (NYSE:PRGO) should be aware of the most powerful shareholder groups. Large...
U.S. stocks fell on Wednesday, as a clutch of weak economic data from the United States and China sparked worries of slowing global growth against the backdrop of a bitter trade dispute that has roiled financial markets. Domestic data showed retail sales unexpectedly fell in April as households cut back on purchases of motor vehicles and a range of other goods, and another report showed declining output of cars and machinery led to a surprise fall in U.S. factory production for April. Meanwhile data from China also showed surprisingly weak growth in retail sales and industrial output for April, adding pressure on the country to roll out more stimulus.
Wall Street was set to open lower on Wednesday, as a surprise fall in domestic retail sales and underwhelming data from China raised growth concerns, while investors waited for more developments on the U.S.-China trade dispute. Government data showed U.S. retail sales unexpectedly fell in April as motor vehicle purchases slumped, while data from China also showed surprisingly weak growth in retail sales and industrial output for April, adding pressure on Beijing to roll out more stimulus. "The U.S. retail sales report is clearly disappointing.
The latest 13F reporting period has come and gone, and Insider Monkey is again at the forefront when it comes to making use of this gold mine of data. We have processed the filings of the more than 700 world-class investment firms that we track and now have access to the collective wisdom contained in […]
FEATURE The S&P 500 was getting hammered this morning amid continued trade fears. Many of the 500 stocks in the index were down Thursday morning, dragging the index down as low as 1.5%. But not every stock was losing.
Perrigo (PRGO) reports encouraging first-quarter 2019 results. The Rx segment recovers during the quarter on strong new product sales.
was gaining more than 5% Thursday after announcing the all-cash acquisition of privately-held Ranir Global Holdings in a deal valued at $750 million. Ranir is the largest private label oral care company in the world, according to Perrigo, with a portfolio of more than 300 oral care products including toothbrush heads and whitening strips. "The addition of Ranir to the Perrigo family illustrates a key component of our new strategy, accelerating growth by pursuing adjacent self-care categories.
Perrigo Co. said Thursday that it has reached an agreement to acquire privately-held oral care company Ranir Global Holdings LLC in a $750 million all-cash deal, or $685 million including cash tax benefits. The announcement is part of a transformation strategy that the self-care company unveiled during its investor day event. Ranir's portfolio includes more than 300 oral care items including manual toothbrushes, floss and dentures. The deal is expected to be about 10 cents per share accretive to 2019 adjusted earnings based on a third-quarter closing. The move is part of Perrigo's strategy to grow in self-care adjacent areas of business, according to a statement from Chief Executive Murray Kessler. Ranir has 650 employees and generated $287 million in net sales in 2018. Annual operating synergies between the two companies are expected to be about $10 million by 2021. The company also reaffirmed its plans to sell or spin off the generic pharmaceuticals business by the end of 2019 or in 2020; divest the animal health business through a $185 million cash deal with PetIQ Inc. ; investing more than $250 million in incremental capital over the next four years to expand the infant nutrition and tablet manufacturing businesses; and launching a cost savings program that will generate $100 million in annualized cost savings. Perrigo is also in discussions with several cannabidiol (CBD) companies to create products, among other innovations the company is pursuing. For 2019, Perrigo is guiding for sales between $4.6 billion and $4.7 billion, EPS between $1.24 and $1.54, and adjusted EPS of $3.65 to $3.95. The FactSet consensus is for sales of $4.7 billion and EPS of $4.14. Perrigo shares are up 27% for the year to date while the S&P 500 index has gained nearly 15%.
Chief Executive Officer and President Murray S. Kessler, along with several key members of his leadership team, will share the Company's strategic plan, vision, and financial objectives while introducing their priorities for transforming Perrigo from a healthcare company to a consumer self-care company. Kessler commented, "We have begun the process of transformation to recapture what we call 'The Perrigo Advantage'. The team has been hard at work during my first six months as CEO, analyzing our challenges and most importantly, building actionable plans to reinvent the company.
Combines Two Consumer-Focused Self-Care Companies Dedicated to Meeting Customer Needs; Expands Ability to Deliver Millions of Affordable Healthy Smiles Worldwide GRAND RAPIDS, Mich. , May 9, 2019 /PRNewswire/ ...
DUBLIN, May 9, 2019 /PRNewswire/ -- Perrigo Company plc (NYSE, TASE: PRGO) today announced that it has reached a definitive agreement to purchase privately-held Ranir Global Holdings LLC ("Ranir") in a transaction valued at $750 million on a cash-free, debt-free basis, or approximately $685 million net of cash tax benefits on a present value basis. Ranir is the largest private label oral care company globally, with a comprehensive portfolio of 300+ highly customized oral care solutions including power toothbrush heads, power toothbrush handles, whitening strips, manual toothbrushes, floss, dentures and travel kits that it sells into over 50 countries worldwide.
Perrigo (PRGO) delivered earnings and revenue surprises of 13.83% and 2.20%, respectively, for the quarter ended March 2019. Do the numbers hold clues to what lies ahead for the stock?
The Dublin-based company said it had net income of 47 cents per share. Earnings, adjusted for one-time gains and costs, came to $1.07 per share. The results beat Wall Street expectations. The average estimate ...
DUBLIN , May 8, 2019 /PRNewswire/ -- GAAP ("reported") net sales were $1.2 billion , reflecting a 4% decline versus the prior year period, or down 1% excluding the unfavorable impact of currency. ...
TASE: PRGO), today announced that it has reached a definitive agreement to sell its Animal Health business to PetIQ (PETQ) in a transaction valued at $185 million in cash. Perrigo CEO and President Murray S. Kessler commented, "We are pleased to have reached an agreement with PetIQ on selling our Animal Health business and look forward to working with them to ensure a seamless transition. In calendar year 2018, Perrigo realized $94 million in net sales and $0.08 of adjusted diluted EPS from the Animal Health business.
First Quarter 2019 Net Sales Increased 29% Year-Over-Year to $148.4 MillionReiterates Full Year 2019 Outlook Enters Into Definitive Agreement to Acquire Perrigo Animal Health.
Perrigo Company PLC NYSE:PRGOView full report here! Summary * ETFs holding this stock are seeing positive inflows but are weakening * Bearish sentiment is moderate and increasing * Economic output in this company's sector is expanding Bearish sentimentShort interest | NeutralShort interest is moderate for PRGO with between 5 and 10% of shares outstanding currently on loan. This represents an increase in short interest as investors who seek to profit from falling equity prices added to their short positions on April 12. Money flowETF/Index ownership | NegativeETF activity is negative and may be weakening. The net inflows of $1.34 billion over the last one-month into ETFs that hold PRGO are among the lowest of the last year and appear to be slowing. Economic sentimentPMI by IHS Markit | PositiveAccording to the latest IHS Markit Purchasing Managers' Index (PMI) data, output in the Healthcare sector is rising. The rate of growth is strong relative to the trend shown over the past year, and is accelerating. Credit worthinessCredit default swapCDS data is not available for this security.Please send all inquiries related to the report to firstname.lastname@example.org.Charts and report PDFs will only be available for 30 days after publishing.This document has been produced for information purposes only and is not to be relied upon or as construed as investment advice. To the fullest extent permitted by law, IHS Markit disclaims any responsibility or liability, whether in contract, tort (including, without limitation, negligence), equity or otherwise, for any loss or damage arising from any reliance on or the use of this material in any way. Please view the full legal disclaimer and methodology information on pages 2-3 of the full report.
Perrigo (PRGO) is focused on Consumer Healthcare Americas segment. Let's see if it aids the company's results in the soon-to-be reported quarter.
TASE: PRGO), today announced that it will release its first quarter calendar year 2019 financial results on May 8, 2019 after market close in the U.S. and will discuss the results and 2019 guidance at its Investor Day on May 9, 2019. The company also announced that Perrigo President and Chief Executive Officer, Murray S. Kessler, will present at the 2019 Goldman Sachs Global Staples Forum at 2:00 PM EDT on Tuesday, May 14, 2019. Perrigo Company is dedicated to making lives better by bringing "Quality, Affordable Self-care Products™" that consumers trust everywhere they are sold. The Company is a leading provider of over-the-counter health and wellness solutions that enhance individual well-being by empowering consumers to proactively prevent or treat conditions that can be self-managed. Visit Perrigo online at (http://www.perrigo.com).
tumbled 7.3% to $47.67 Tuesday after the pharmaceutical company said it had received an $843 million bill from the Internal Revenue Service. The Dublin-based company said in a filing that it had gotten a revised Notice of Proposed Adjustment from the IRS examination team auditing Athena Neurosciences Inc. for the years ended Dec. 31, 2011 - 2013. Athena was acquired as a U.S. subsidiary by Elan Corp. in 1996 and Perrigo acquired Elan through a December 2013 business combination between Perrigo's predecessor and Elan.
Perrigo Company Plc announced Friday it would be increasing its quarterly dividend by 11% from 19 cents to 21 cents. The new dividend will be payable on June 18 to investors who own the stock at the close of business on May 31. This will be the sixteenth consecutive year the health company has increased its dividend. Shares of Perrigo have gained 29% in the year to date, while the S&P 500 has gained 16.7%.